Li Zhaozhong, Song Yanfang, Lin Zhen, Zhang Taigang, He Aoyu, Shi Pengcong, Zhang Xiaoli, Cao Yinping, Zhu Xianjin
Department of Laboratory Medicine, Fujian Medical University Union Hospital No. 29 Xinquan Road, Fuzhou 350001, Fujian, China.
Clinical Laboratory, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine No. 602 Bayiqi Road, Fuzhou 350001, Fujian, China.
Am J Cancer Res. 2024 Jul 15;14(7):3388-3403. doi: 10.62347/CKMT4065. eCollection 2024.
The drug resistance is a major obstacle in acute B-lymphoblastic leukemia (B-ALL) treatment. Our previous study has indicated that increased levels of Cysteine-rich protein 61 (Cyr61) in the bone marrow can mitigate the chemosensitivity of B-ALL cells, though the specific source of Cyr61 in the bone marrow remains unknown. In this study, we aimed to investigate whether hypoxia can induce Cyr61 production in B-ALL cells, delineates the underlying mechanisms, and evaluates the effect of Cyr61 on the chemosensitivity of B-ALL cells under hypoxia conditions. The results indicate that hypoxia promotes Cyr61 production in B-ALL cells by activating the NF-κB pathway. Increased Cyr61 expression appears to reduce the chemosensitivity of B-ALL cell to vincristine (VCR) and daunorubicin (DNR) through autophagy under hypoxia. Notably, inhibition of Cyr61 restores the chemosensitivity of B-ALL cells to both chemotherapeutic agents. This study is the first time to report that hypoxia decreases the chemosensitivity of B-ALL cells by inducing Cyr61 production, suggesting that targeting Cyr61 or its associated pathways could potentially improve the clinical response of B-ALL patients.
J Cancer Res Clin Oncol. 2024-3-26
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014-6
Biomark Med. 2022-10
Cancers (Basel). 2022-10-17
Transl Androl Urol. 2021-8
Biomed Pharmacother. 2021-9
Cancer Control. 2021